Results of this preplanned interim analysis demonstrated significantly improved DFS with adjuvant atezolizumab in patients with stage II-IIIA NSCLC, particularly for individuals with PD-L1–positive tumors.
DESTINY-Lung02 interim analyses: efficacy/safety of 2 doses of T-DXd (5.4 mg/kg and 6.4 mg/kg) in patients with HER2-mutated NSCLC and at least 1 previous therapy, presented at ESMO 2022 and reported by Clinical Care Options (CCO)
Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC
Expert faculty share patient case examples from clinical practice that highlight the importance of biomarker testing for NSCLC, from Clinical Care Options (CCO)
Phase III CodeBreaK 200 study of sotorasib vs docetaxel in previously treated KRAS G12C-mutated advanced non-small-cell lung cancer, presented at ESMO 2022 as reported by Clinical Care Options (CCO)